Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2012. The report details a specific share repurchase transaction executed on October 11, 2012, pursuant to shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 500,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,439.5 pence per share; lowest price paid was 1,424.5 pence per share.
- Treasury Holdings (Settled): 504,840,427 shares (9.27% of total issued share capital).
- Treasury Holdings (Including Unsettled): 506,310,427 shares (10.25% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,940,229,100 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 500,000 shares for Treasury. This action increased the percentage of total voting rights held in Treasury from the prior level to 10.25% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase or subscribe for securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (504,840,427 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (4,940,229,100 shares in issue) for disclosure threshold assessments.
- Review the price paid per share (1,424.5 to 1,439.5 pence) to assess the cost of capital reduction relative to market prices on October 11, 2012.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial results.